Zhejiang Hisoar Pharmaceutical Co.Ltd(002099) 28 said on the investment interactive platform that technology development and project investment are the main ways of “extension” development of the company, and Huayi Taikang and Pfizer projects are mainly implemented in Taizhou production base. The company will make use of its capital advantages according to its own needs and expand its future space through various investment platforms.
It is reported that Shanghai Hengfeng Pharmaceutical Technology Development Co., Ltd., a wholly-owned subsidiary of Zhejiang Hisoar Pharmaceutical Co.Ltd(002099) has been established on February 9, 2022, with a registered capital of 450 million yuan and a legal representative of Tao Hong. The business scope includes general projects: technical consultation, technology transfer, technical service and technology development in the professional field of medical science and technology.
